Deepika Rao

Deepika Rao

Auto-generated profile, based on publicly available information

Deepika Rao

Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Health Psychology and Behavioral Medicine
Verified
Journal Article
Open access
OSOlayinka O Shiyanbola
Olayinka O Shiyanbola
DRDeepika Rao
Deepika Rao
DBDaniel Bolt
Daniel Bolt
CBCarolyn Brown
Carolyn Brown
MZMengqi Zhang
Mengqi Zhang
EWEarlise Ward
Earlise Ward
Although qualitative methods have been used to develop quantitative behavioral health measurements, studies rarely report on the exact development process of these questionnaires. In this methodolo...

1 September 2020 in Substance Abuse
Verified
Journal Article
Closed access
DRDeepika Rao
Deepika Rao
VGVincent Giannetti
Vincent Giannetti
KKKhalid M. Kamal
Khalid M. Kamal
JCJordan R Covvey
Jordan R Covvey
JTJohn R. Tomko
John R. Tomko
Background: Community pharmacists can play a meaningful role in identification and treatment of substance use disorders (SUD). However, inadequate disease knowledge and negative attitudes are known barriers. The relationship between knowledge, attitudes, and practice of pharmacists regarding persons with SUD has not been evaluated comprehensively in the United States. The objective of the study was to assess knowledge of community pharmacists regarding medications for SUD and evaluate their attitudes, levels of stigma, and clinical practices in SUD. Methods: A questionnaire was developed to assess practices, knowledge, screening services, and attitudes toward harm reduction strategies and treatment. A standardized measure of stigma was included along with demographics. A cross-sectional electronic survey was conducted in Pennsylvania, Ohio, and West Virginia among a non-probability sample of community pharmacists working for a retail pharmacy chain (n = 910) and a local alumni network ( n = 50). Scores were calculated for each factor and descriptive analyses, mean differences ( t -tests and ANOVA), correlations with demographics and practice characteristics were performed. Linear and ordinal regressions were utilized to predict knowledge, practice, screening, and stigma scores. Results: A total of 134 responses (response rate 13.9%) were collected. On average, the pharmacists were 38 years old, had worked for 15 years, primarily full-time with practice locations in suburban settings. Only 53% reported they received SUD education in pharmacy school. Pharmacists received a mean score of 5.5 and 3.5 out of eight and seven on knowledge and practice scales, respectively. Pharmacists overall had slightly stigmatizing and negative attitudes, with higher stigma significantly related to performing lesser services and considering screenings as important. Number of years worked significantly predicted knowledge and screening. Conclusion: Relationships between knowledge, attitudes, and practices indicate a need for experiential education that includes psychosocial aspects of care with increased opportunities for practice.

1 January 2022 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
DRDeepika Rao
Deepika Rao
OSOlayinka O. Shiyanbola
Olayinka O. Shiyanbola

25 August 2021 in Substance Use & Misuse
Verified
Journal Article
Closed access
DRDeepika Rao
Deepika Rao
VGVincent Giannetti
Vincent Giannetti
KKKhalid M. Kamal
Khalid M. Kamal
JCJordan R. Covvey
Jordan R. Covvey
JTJohn R. Tomko
John R. Tomko
Community pharmacists have significant opportunity to contribute to prevention and treatment of opioid use disorders, but barriers to implementation still exist. Understanding their viewpoints is c...

17 May 2023 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
DRDeepika Rao
Deepika Rao
MMMeg Mercy
Meg Mercy
CMChristine McAtee
Christine McAtee
James Ford IIJames Ford II
James Ford II
OSOlayinka O Shiyanbola
Olayinka O Shiyanbola

7 April 2022 in Journal of Dual Diagnosis
Verified
Journal Article
Closed access
James Ford IIJames Ford II
James Ford II
DRDeepika Rao
Deepika Rao
AGAaron Gilson
Aaron Gilson
AKArveen Kaur
Arveen Kaur
HGHelene Chokron Garneau
Helene Chokron Garneau
MMMark P. McGovern
Mark P. McGovern
Objective: Community addiction treatment agencies have utilized Network for the Improvement of Addiction Treatment (NIATx), a proven implementation strategy, to reduce appointment wait-times. However, its effectiveness at reducing medication access wait-times has not been explored. Thus, we conducted an exploratory analysis to evaluate the impact of the NIATx implementation strategies on reduced wait-times to addiction, psychotropic or both medications for individuals with co-occurring disorders (COD). Methods: In a cluster-randomized waitlist control group design, community addiction treatment agencies (n = 49) were randomized to receive the NIATx strategy (Cohort 1, n = 25) or to a Waitlist control (Cohort 2, n = 24). All agencies had a 12-month active intervention period. The primary outcome was the medication encounter wait-time. A univariate general linear model analysis utilizing a logarithmic (log10) transformation examined medication wait-times improvements. Results: The intent-to-treat analysis for psychotropic medications and both medications (reflecting integrated treatment) showed significant main effects for intervention and time, especially comparing Baseline and Year 1 to Year 2. Conversely, only the main effect for time was significant for addiction medications. Wait-time reductions in Cohort 1 agencies was delayed and occurred in the sustainment phase. Wait-times to a psychotropic, addiction, or both medications encounter declined by 3 days, 4.9 days, and 6.8 days, respectively. For Cohort 2 agencies, reduced wait-times were seen for psychotropic (3.4 days), addiction (6 days), and both medications (4.9 days) during their active implementation period. Same- or next-day medication access also improved. Conclusions: NIATx implementation strategies reduced medication encounter wait-times but timing of agency improvements varied. Despite a significant improvement, a three-week wait-time to receive integrated pharmacological interventions is clinically suboptimal for individuals with a COD in need of immediate intervention. Community addiction treatment agencies should identify barriers and implement changes to improve medication access so that their patients “wait no longer” to receive integrated treatment and medications for their COD.